Health-related quality of life (HRQL) and patient-reported outcome (PRO) have become important outcome parameters for the evaluation of medical treatment within clinical trials and, furthermore, to evaluate efficiency in clinical practice. We therefore report further exploratory results of an already reported dose-finding study with EPs 7630 tablets, now focussing on HRQL and PRO. A total of 406 adults with acute bronchitis were randomly assigned to one of four parallel treatment groups (placebo, 30 mg, 60 mg or 90 mg EPs 7630 daily). HRQL and PRO were assessed by questionnaires as secondary outcome measures at each study visit or daily in the patient's diary. At day 7, the patient-reported outcome measures were significantly more improved in all the three EPs 7630 groups compared to placebo (EQ-5D and EQ VAS, SF-12: physical score, impact of patient's sickness, duration of activity limitation, patient-reported treatment outcome, satisfaction with treatment). In conclusion, a statistically significant and clinically relevant improvement of HRQL/PRO compared to placebo was shown in all the three EPs 7630 groups.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10354-010-0847-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unlocking the therapeutic potential of natural extract: A scoping review.
Heliyon
December 2024
Department of Social Dentistry, School of Dentistry, São Paulo State University (UNESP), R. Humaitá, 1680, Araraquara, SP, 14801-385, Brazil.
DC. (Geraniaceae) is a widely recognized medicinal plant whose natural extract exhibits therapeutic effects through a multi-target approach. Existing literature encompasses investigations of antimicrobial and cellular effects, including clinical trials.
View Article and Find Full Text PDFMultiple mechanisms enable broad-spectrum activity of the root extract EPs 7630 against acute respiratory tract infections.
Front Pharmacol
October 2024
Interdisciplinary Laboratory for Tumour and Virus Research, Dr Petra Joh Research Institute, Frankfurt am Main, Germany.
Article Synopsis
- EPs 7630 is a clinically proven plant extract that effectively treats various acute respiratory infections while reducing antibiotic use, which is crucial amid increasing antibiotic resistance.
- It works through multiple mechanisms, including antibacterial, antiviral, and immunomodulatory effects, allowing it to address respiratory infections at different stages of the disease.
- The findings suggest that plant extracts like EPs 7630 have significant potential as evidence-based treatments, warranting further research and testing like conventional medications.
Hand, foot, and mouth disease: could EPs® 7630 be a treatment option? A prospective randomized open-label multicenter clinical study.
Front Pediatr
May 2024
Pediatric Infectious Diseases, Faculty of Medicine, Hacettepe University, Ankara, Türkiye.
Article Synopsis
- Hand, foot, and mouth disease (HFMD) is a viral infection in children caused by enteroviruses and coxsackieviruses, with no specific treatment options available.
- A clinical study with 208 children investigated the effects of EPs® 7630, an herbal medicine, on HFMD symptoms, revealing significantly shorter illness duration and lower hospitalization rates in the treatment group compared to controls.
- The results suggest that EPs® 7630 is a potentially effective and safe herbal treatment for HFMD, with only minor side effects reported.
Long-term benefits of EPs 7630 in patients with acute sinusitis: a real-world cohort study.
Front Pharmacol
March 2024
IQVIA, Epidemiology, Frankfurt am Main, Germany.
We evaluated whether EPs 7630 prescription in patients with acute sinusitis (AS) is associated with less frequent recurrence of AS, occurrence of chronic sinusitis or nasal polyps, or fewer antibiotic prescriptions. This retrospective cohort study used electronic medical records from the IQVIA Disease Analyzer database. Associations between initial therapy [EPs 7630, antibiotics, intranasal corticosteroid (INCS), or corticosteroid-free nasal spray within 3 days of AS diagnosis] and AS recurrence, incidence of chronic sinusitis or nasal polyps or rate of antibiotic prescription were studied using multivariable Cox or logistic regression models, adjusting for sex, age, insurance status, month of diagnosis, and comorbidity.
View Article and Find Full Text PDFIdentifying in-market application of Pelargonium root extract EPs 7630 for the treatment of COVID-19: analysis of pharmacovigilance data.
Front Pharmacol
February 2024
Research and Development, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
Phytopharmaceutical products are successfully used for acute respiratory infections and may therefore be promising candidates for adjuvant symptomatic treatment of COVID-19. and clinical studies suggest that the proprietary root extract EPs 7630 has antiviral and immunomodulatory properties, and effects on SARS-CoV-2 propagation have been shown . Medicinal products containing the extract have been approved for the symptomatic treatment of acute viral respiratory tract infections.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!